Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome

American Journal of Gastroenterology

Volumn 96, Issue 9 SUPPL., 2001, Pages 2671-2676

  Viramontes, Blanca E ^a   Camilleri, Michael ^a   McKinzie, Sanna ^a   Pardi, Darrell S ^a   Burton, Duane ^a   Thomforde, George M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; SEROTONIN 3 ANTAGONIST;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DATA ANALYSIS; DIARRHEA; DRUG EFFECT; FEMALE; HUMAN; INTESTINE TRANSIT TIME; IRRITABLE COLON; MALE; NAUSEA; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; CARBOLINES; COLON; COLONIC DISEASES, FUNCTIONAL; DIARRHEA; FEMALE; GASTROINTESTINAL TRANSIT; HUMANS; MALE; SEROTONIN ANTAGONISTS; SEX FACTORS; TIME FACTORS;

EID: 0034821162     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)02700-9     Document Type: Article

References (31)

1. Irritable bowel syndrome in office-based practice in the United States
2. Irritable bowel syndrome
3. Basic and clinical aspects of visceral hyperalgesia
4. Irritable bowel syndrome: A technical review for practice guideline development
5. Irritable bowel syndrome: Relationship of disorders in the transit of a single solid meal to symptom patterns
6. Transit through the proximal colon influences stool weight in the irritable bowel syndrome
7. Altered rectal perception is a biological marker of patients with irritable bowel syndrome
8. Serotonergic mediation of postprandial colonic tonic and phasic responses in humans
9. 3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea
10. 3 antagonist, alosetron, in patients with carcinoid diarrhoea
11. Clinical pharmacology of alosetron
12. 3-receptor antagonist
13. 3 receptor antagonist, delays colonic transit in both patients with irritable bowel syndrome, and healthy volunteers
14. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome
15. Functional bowel disorders and functional abdominal pain
16. Human gastric emptying and colonic filling of solids characterized by a new method
17. Transit of solids through the human colon: Regional quantification in the unprepared bowel
18. Towards a less costly but accurate test of gastric emptying and small bowel transit
19. Towards a relatively inexpensive, noninvasive, accurate test for colonic motility disorders
20. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydrxytryptamine receptor (type 3) antagonist
21. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man
22. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome. A pilot study
23. Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo-controlled trial
24. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5HT3 receptor antagonist, in patients with irritable bowel syndrome
25. 3 mediation of human gastrocolonic response and colonic peristaltic reflex
26. 3 antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome
27. Alosetron does not affect the visceral perception of gastric distension in healthy subjects
28. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome
29. A pilot study of motility and tone of the left colon in diarrhea due to functional disorders and dysautonomia
30. In vivo effects of the 5-HT3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: A segmental perfusion study
31. 3 receptors on spinal primary afferents projecting to the colon of the rat - A peripheral target for alosetron